AI brief of an SEC Form 8-K · Protalix BioTherapeutics, Inc. (PLX)

Protalix Q3 net income rises to $4.0 million; 2026 revenue guidance reaffirmed

Positive Impact 3 of 5 earnings

Protalix reported third-quarter 2026 total revenue of $21.9 million, up from $17.9 million a year earlier, and net income of $4.0 million, or $0.05 per share, compared with $2.4 million, or $0.03 per share. Nine-month revenue reached $75.6 million versus $43.6 million, and the company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million, which includes a $25.0 million Chiesi milestone received in the first quarter. For shareholders, revenue and profit rose year over year, cash and short-term deposits totaled $48.5 million at September 30, 2026, and the company reported no outstanding debt or warrants.

Key points

  • Q3 2026 net income was $4.0 million ($0.05 per share, basic and diluted) versus $2.4 million ($0.03 per share) in Q3 2025
  • Nine-month 2026 total revenue was $75.6 million versus $43.6 million, including a $25.0 million Chiesi milestone received in Q1 2026
  • 2026 total revenue guidance of $78.0 million to $83.0 million was reaffirmed, with the company expecting to meet or exceed these ranges
  • Cash, cash equivalents and short-term bank deposits were $48.5 million at September 30, 2026; the company has no outstanding debt or warrants

The filing

CompanyProtalix BioTherapeutics, Inc. (PLX)
Form8-K, current report
Filed with the SECNov 10, 2026, 6:54 AM ET
Accession number0001104659-26-124761

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:01 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.